Pharma’s new and exciting era of targeted therapeutics has the potential to be a turning point for modern medicine. The buzz has led to a flurry of investment in the cell and gene therapy space. According to a recent Alliance for Regenerative Medicine report, nearly...
The biopharma industry was certainly not immune to the turbulence brought about by the COVID-19 pandemic. The pandemic disrupted — and in some cases, stopped completely — clinical trials around the globe. In fact, as of January 2021, more than 2,000 clinical trials...
While incidents of biotherapeutic viral contamination have occurred, due to well-established knowledge of the potential sources of contamination and procedures to prevent it, the industry has an impressive track record. Biologics are susceptible to viral contamination...
Jeanette Young, senior consultant for analytical services at BioTechLogic talks with Tonia Becker, Life Sciences Editor, Macon Raine As it became clear that the COVID-19 pandemic would not be a short-lived disruption, gene and cell therapy companies adjusted their...
It’s a fascinating time to be in the biotherapeutics industry. What will the remarkedly rapid COVID-19 vaccine development effort teach us about how to develop and scale vaccines quickly for future crises? Additionally, the gene therapy sector continues to mature,...
The gene therapy sector is maturing and the industry is poised to be able to produce products in more consistent and scalable ways. Although the COVID-19 pandemic caused some delays, on the whole, projects are moving forward as planned. I had the opportunity to speak...
